Form 4: BridgeBio Pharma Director Sells 100,000 Shares Under Pre-Arranged Plan

BridgeBio Pharma, Inc. Director Frank McCormick sold 100,000 shares of common stock for approximately $4.42 million on June 24, 2025, under a Rule 10b5-1 trading plan.

Summary

• Frank McCormick, a Director of BridgeBio Pharma, Inc. (BBIO), reported a sale of common stock.
• The transaction involved the disposition of 100,000 shares of common stock.
• The sale occurred on June 24, 2025.
• The shares were sold at a weighted average price of $44.228 per share, with prices ranging from $44.00 to $44.69.
• This transaction was executed pursuant to a Rule 10b5-1 sales plan adopted by Mr. McCormick on August 28, 2024.
• Following the transaction, Mr. McCormick beneficially owns 879,979 shares indirectly through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares directly.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while a divestment, was conducted under a pre-arranged Rule 10b5-1 plan, which mitigates the immediate negative sentiment often associated with insider selling, suggesting a planned financial management action rather than a reaction to new negative information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on August 28, 2024, indicating a planned transaction rather than a reaction to immediate market conditions.

Negatives

• A director, Frank McCormick, sold a significant number of shares (100,000) of common stock.
• The sale value of approximately $4.42 million represents a substantial divestment by an insider.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's future prospects, potentially leading to negative investor sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a director could be perceived negatively, potentially impacting investor confidence, although the 10b5-1 plan mitigates this to some extent.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, BBIO, Frank McCormick, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Pharmaceutical, Biotech